Infection
Update

Topics

toumei ../../image Congress Report




Aventis Pharma/Daiichi Pharmaceutical Co., Ltd. Joint-Sponsered Symposium at the 12th ECCMID 2002

Chairman: Francesco Blasi, Italy


The annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) is recognized as one of the most important and influential meetings in the world of infection. In line with previous meetings, the 12th ECCMID, held in Milan, Italy on April 24-27th, 2002, comprised a comprehensive scientific program focusing on new discoveries and treatments in clinical microbiology and recent developments in the understanding of the pathogenesis, epidemiology and diagnosis of infectious diseases. As usual, ECCMID attracted attendance from a wide range of disciplines, including clinical microbiologists, infection-control specialists, biomedical researchers and physicians.

One of the major themes of the congress was the increasingly widespread resistance of the major respiratory pathogens to traditional therapies. However, exciting data on the widespread activity and low incidence of resistance to fluoroquinolones suggests that these agents may be considered as alternative therapies in problematic cases.

This report summarizes the data presented at an Aventis integrated symposium, held on April 25th, 2002, which discussed new developments in the treatment of respiratory infections, especially with reference to the evolving problem of resistance. New data was presented that confirmed the important role of levofloxacin and other fluoroquinolones in the management of respiratory infections.


Programme:
toumei ../../image    
  To read the reports click on the title.
toumei ../../image    
15.30-15.35

Chairman's Introduction
Francesco Blasi MD, PhD
Institute of Respiratory Diseases, University of Milan, Italy
toumei ../../image   Biography     
toumei ../../image    
15.35-16.00
Antibacterial activity of new Fluoroquinolones
David Felmingham MSc
GR Micro Ltd, London, UK
toumei ../../image   Biography     
toumei ../../image    
16.00-16.25
Clinical meaning of resistance in Respiratory Infections
Javier Garau MD
University of Barcelona and Hospital Mutua de Terrassa, Barcelona, Spain
toumei ../../image   Biography     
toumei ../../image    
16.25-16.50
Pharmacokinetic properties of new Fluoroquinolones and their use in Respiratory Infections
George Drusano MD
Albany Medical College, Albany, New York, USA
toumei ../../image   Biography     
toumei ../../image    
16.50-17.15
The role of new Fluoroquinolones in treatment of Respiratory Infections
Tobias Welte MD, PhD
Department of Pneumology, Otto-von-Guericke-University Magdeburg, Germany
toumei ../../image   Biography     
toumei ../../image    
17.15-17.30
  Roundtable Discussion
toumei ../../image    


to_top

©This highlight has been developed by Diagnosis Healthcare Communications


 

.
  ©1998- BIOMEDIS International, Ltd. All rights reserved. Reproduction in any manner in whole or part prohibited.
Disclaimer
Last updated April 26, 2002